Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$8.23 USD
+0.58 (7.58%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $8.26 +0.03 (0.36%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
KYTX 8.23 +0.58(7.58%)
Will KYTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for KYTX
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Buy Rating for Kyverna Therapeutics Amid FDA Clearance and Promising Phase 2 Trial Prospects
Oppenheimer doesn't understand why Cartesian hit by emerging CAR-T short thesis
Kyverna Therapeutics participates in a conference call with JPMorgan
Kyverna Therapeutics participates in a conference call with JPMorgan